CALT vs. GHRS, ANAB, CVAC, PHAR, MLYS, LYEL, COGT, ZYME, SVRA, and SLN
Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include GH Research (GHRS), AnaptysBio (ANAB), CureVac (CVAC), Pharming Group (PHAR), Mineralys Therapeutics (MLYS), Lyell Immunopharma (LYEL), Cogent Biosciences (COGT), Zymeworks (ZYME), Savara (SVRA), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical preparations" industry.
GH Research (NASDAQ:GHRS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Calliditas Therapeutics AB (publ) received 7 more outperform votes than GH Research when rated by MarketBeat users. However, 67.86% of users gave GH Research an outperform vote while only 60.47% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
56.9% of GH Research shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
GH Research presently has a consensus price target of $36.67, suggesting a potential upside of 175.69%. Calliditas Therapeutics AB (publ) has a consensus price target of $34.00, suggesting a potential upside of 53.50%. Given Calliditas Therapeutics AB (publ)'s stronger consensus rating and higher probable upside, analysts clearly believe GH Research is more favorable than Calliditas Therapeutics AB (publ).
GH Research has a net margin of 0.00% compared to GH Research's net margin of -38.72%. Calliditas Therapeutics AB (publ)'s return on equity of -14.56% beat GH Research's return on equity.
GH Research has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). GH Research is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.
GH Research has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
In the previous week, Calliditas Therapeutics AB (publ) had 6 more articles in the media than GH Research. MarketBeat recorded 8 mentions for Calliditas Therapeutics AB (publ) and 2 mentions for GH Research. GH Research's average media sentiment score of 0.37 beat Calliditas Therapeutics AB (publ)'s score of 0.17 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.
Summary
GH Research beats Calliditas Therapeutics AB (publ) on 10 of the 17 factors compared between the two stocks.
Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calliditas Therapeutics AB (publ) Competitors List
Related Companies and Tools
